Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809

Cancer

Volumn 117, Issue 24, 2011, Pages 5579-5588

  Hurwitz, Mark D ^a,b   Halabi, Susan ^c   Archer, Laura ^c   McGinnis, Lamar S ^d   Kuettel, Michael R ^e   Dibiase, Steven J ^f   Small, Eric J ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d PRESBYTERIAN HOSPITAL   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

brachytherapy; cooperative group trial; hormonal therapy; prostate; radiation

Indexed keywords

ANTIANDROGEN; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION INJURY; SCORING SYSTEM; SEMINAL VESICLE; TREATMENT FAILURE; TREATMENT RESPONSE; UNITED STATES;

EID: 83055195247     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26203     Document Type: Article

References (25)

1. Dattoli M, Wallner K, Sorace R, et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostate carcinoma. Int J Radiat Oncol Biol Phys. 1997; 39: 776-777.
2. Ragde H, Blasko JC, Grimm PD, et al. Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. Semin Surg Oncol. 1997; 13: 438-443. (Pubitemid 27469228)
3. Stone NN, Stock RG,. Prostate brachytherapy: treatment strategies. J Urol. 1999; 162: 421-426. (Pubitemid 29434353)
4. Lee WR, DeSilvio M, Lawton C, et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006; 64: 804-809. (Pubitemid 43183578)
5. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007; 109: 1506-1512. (Pubitemid 46595685)
6. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007; 67: 57-64. (Pubitemid 44959493)
7. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer. 2007; 110: 551-555. (Pubitemid 47106143)
8. Critz FA, Williams WH, Levinson AK, et al. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol. 2000; 164 (3 pt 1): 738-741.
9. Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005; 61: 32-43. (Pubitemid 40039102)
10. Singh AM, Gagnon G, Collins B, et al. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis. Prostate. 2005; 62: 54-60. (Pubitemid 39614294)
11. Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 59: 1352-1359. (Pubitemid 38954057)
12. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827. (Pubitemid 39079668)
13. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-295. (Pubitemid 351159365)
14. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850. (Pubitemid 41614795)
15. McGowan D, Hunt D, Jones C, et al. Short term androgen deprivation prior to and during radiation therapy improves overall survival in patients with t1b-t2b adenocarcinoma of the prostate and PSA ≤20: initial results of RTOG 94-08 [abstract]. ASTRO 2009.
16. Stock RG, Stone NN, Cesaretti JA,. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 2003; 56: 448-453. (Pubitemid 36542902)
17. Cavanagh W, Blasko JC, Grimm PD, et al. Transient elevation of serum prostate-specific antigen following I/Pd brachytherapy for localized prostate cancer. Semin Urol Oncol. 2000; 18: 160-165. (Pubitemid 30395868)
18. Critz FA, Williams WH, Benton JB, et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000; 163: 1085-1089. (Pubitemid 30169367)
19. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003; 57: 929-943. (Pubitemid 37324110)
20. Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
21. Hurwitz MD, Halabi S, Ou SS, et al. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008; 72: 814-819.
22. Benoit RM, Naslund MJ, Cohen JK,. Complications after prostate brachytherapy in the Medicare population. Urology. 2000; 55: 91-96. (Pubitemid 30050764)
23. Zelefsky MJ, Fuks Z, Wolfe T, et al. Locally advanced prostatic cancer: long-term toxicity outcome after 3-dimensional conformal radiation therapy-a dose-escalation study. Radiology. 1998; 209: 169-174. (Pubitemid 28464663)
24. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 47: 1261-1266. (Pubitemid 30421178)
25. Giordano SH, Lee A, Kuo YF, et al. Late gastrointestinal toxicity after radiation for prostate cancer. Cancer. 2006; 107: 423-432. (Pubitemid 44036573)